Dr. Fairchild specializes in the diagnosis, evaluation and management of rheumatologic diseases. He has a particular interest in musculoskeletal ultrasound and heads the Division of Immunology and Rheumatology's Diagnostic and Interventional Musculoskeletal Ultrasound Clinic. Dr. Fairchild, received his Ph.D. from Georgetown University, and his M.D. from Columbia University College of Physicians and Surgeons. He completed internship and residency in the Department of Medicine at Stanford University. He continued on at Stanford, completing his fellowship in rheumatology and subsequently joined the faculty of the Division of Immunology and Rheumatology. He trained in rheumatologic musculoskeletal ultrasound through the USSONAR program and is certified in this technique through the American College of Rheumatology (RhMSUS certification). Dr. Fairchild’s research interests center on novel applications of ultrasonography in rheumatologic disease.
- Diagnostic and Interventional Rheumatologic Ultrasonography
Clinical Assistant Professor, Medicine - Immunology & Rheumatology
Fellowship:Stanford Immunology and Rheumatology Fellowship (2017) CA
Board Certification: Rheumatology, American Board of Internal Medicine (2017)
Board Certification: Internal Medicine, American Board of Internal Medicine (2015)
Residency:Stanford University Internal Medicine Residency (2015) CA
Internship:Stanford University Internal Medicine Residency (2013) CA
Medical Education:Columbia University College of Physicians and Surgeons (2012) NY
PhD, Georgetown University, Host-Guest and Organometallic Chemistry (2008)
Current Research and Scholarly Interests
Dr. Fairchild’s research interests center on novel applications of ultrasonography in rheumatologic disease. Current active research endeavors include using ultrasound 1) to evaluate articular and soft tissue manifestations of systemic sclerosis, 2) to screen, detect and monitor of connective tissue disease associated interstitial lung disease, 3) and to examine the incidence of immune checkpoint inhibitor related adverse events and inflammatory arthritis. Additionally, Dr. Fairchild is engaged in collaborative work with other rheumatologic ultrasonographers nationally helping to develop consensus on ultrasonography protocols and fellowship training guidelines.
Consensus Statements on Scanning Conventions and Documentation in Musculoskeletal Ultrasound
View details for Web of Science ID 000447268902292
Strongyloides Hyperinfection After Immunosuppression in an Immigrant From El Salvador: A Case for Early Diagnosis and Treatment.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
View details for PubMedID 30074914
Consensus-Building on a Rheumatology Musculoskeletal Ultrasound Scanning Protocol for Rheumatology Fellowship Programs
View details for Web of Science ID 000411824100110
Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
2017; 35 (4): S106–S113
View details for Web of Science ID 000418419000015
Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry.
Clinical and experimental rheumatology
To assess the utility of B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) in detecting and monitoring pulmonary hypertension (PH) in systemic sclerosis (SSc).PHAROS is a multicenter prospective cohort of SSc patients at high risk for developing pulmonary arterial hypertension (SSc-AR-PAH) or with a definitive diagnosis of SSc-PH. We evaluated 1) the sensitivity and specificity of BNP≥64 and NT-proBNP≥210 pg/mL for the detection of SSc-PAH and/ or SSc-PH in the SSc-AR-PAH population; 2) baseline and longitudinal BNP and NT-proBNP levels as predictors of progression to SSc-PAH and/or SSc-PH; 3) baseline BNP≥180, NT-proBNP≥553 pg/mL, and longitudinal changes in BNP and NT-proBNP as predictors of mortality in SSc-PH diagnosed patients.172 SSc-PH and 157 SSc-AR- PAH patients had natriuretic peptide levels available. Median BNP and NT-proBNP were significantly higher in the SSc-PH versus SSc-AR-PAH group. The sensitivity and specificity for SSc-PAH detection using baseline BNP≥64 pg/mL was 71% and 59%; and for NT-proBNP≥210 pg/mL, 73% and 78%. NT-proBNP showed stronger correlations with haemodynamic indicators of right ventricular dysfunction than BNP. Baseline creatinine, RVSP > 40 mmHg, and FVC%:DLco% ratio ≥1.8 were associated with progression from SSc-AR-PAH to SSc-PH but no association with individual or combined baseline BNP and NT-proBNP levels was observed. Baseline and follow-up BNP or NT-proBNP levels were not predictive of death, however, a composite BNP/NT-proBNP group predicted mortality (HR 3.81 (2.08-6.99), p<.0001).NT-proBNP may be more useful than BNP in the detection and monitoring of PAH in SSc patients, but additional studies are necessary.
View details for PubMedID 27908301